ARQT

Arcutis Biotherapeutics Inc

25.55

Nov 06 • 3:59 PM ET -1.45 (-5.37%)

25.72

Aftermarket • 6:18 PM ET +0.17 (0.67%)

Healthcare Biotechnology USA Mid NASD

Nov 05, 11:02 PMArcutis raises 2026 revenue guidance again as ZORYVE demand outperforms seasonal headwinds

Peers: INCY OGN ORKA KRYS MANE EVMN SLGL ALMS DERM VRCA

| Held by: IJR VTI XBI IWM VXF IWO PINK SPSM IJT IBB

Scroll to Statements

Index	RUT
Market Cap	3.23B
Enterprise Value	3.09B
Income	29.91M
Sales	508.68M
Book/sh	1.94
Cash/sh	2.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	354
IPO	Jan 31, 2020

P/E	118.45
Forward P/E	24.33
PEG	-
P/S	6.35
P/B	13.20
P/C	12.44
P/FCF	54.11
EV/EBITDA	81.21
EV/Sales	6.08
Quick Ratio	2.66
Current Ratio	2.92
Debt/Eq	0.51
LT Debt/Eq	0.44
Option/Short	Yes / Yes

EPS (ttm)	0.22
EPS next Y	1.05
EPS next Q	0.20
EPS this Y	312.09%
EPS next Y	280.83%
EPS next 5Y	-
EPS past 3/5Y	71.80% 49.34%
Sales past 3/5Y	367.27% -
EPS Y/Y TTM	165.45%
Sales Y/Y TTM	60.00%
EPS Q/Q	15.23%
Sales Q/Q	45.05%
Earnings	Nov 04 AMC
EPS/Sales Surpr.	-66.67% 0.93%

Insider Own	12.88%
Insider Trans	-1.01%
Inst Own	97.02%
Inst Trans	4.05%
ROA	6.68%
ROE	14.88%
ROIC	8.51%
Gross Margin	91.18%
Oper. Margin	6.91%
Profit Margin	5.88%
SMA20	-15.60%
SMA50	-5.94%
SMA200	0.83%
Trades

Shs Outstand	126.02M
Shs Float	109.51M
Short Float	18.71%
Short Ratio	7.92
Short Interest	20.49M
52W High	34.80 -26.58%
52W Low	19.30 32.42%
Volatility	6.75% 5.53%
ATR (14)	1.88
RSI (14)	38.61
Beta	1.68
Rel Volume	1.26
Avg Volume	2.59M
Volume	3,262,398

Perf Week	-20.33%
Perf Month	4.33%
Perf Quarter	-1.43%
Perf Half Y	20.69%
Perf YTD	-12.02%
Perf Year	1.79%
Perf 3Y	991.88%
Perf 5Y	15.87%
Perf 10Y	-
Recom	1.25
Target Price	40.38
Prev Close	27.00
Price	25.55
Change %	-5.37%

Consensus

Strong Buy

Avg. Price Target

$40.38

Implied Upside

+58.0%

Analysts10incl. previous ratings

Rating Distribution9 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Initiated	CCantor Fitzgerald	Overweight	$48	+87.9%
Jul 25, 2025	Initiated	GGoldman	Neutral	$18	-29.5%
Dec 30, 2024	Initiated	HH.C. Wainwright	Buy	$19	-25.6%
Aug 28, 2024	Initiated	JJefferies	Buy	$15	-41.3%
Jan 03, 2024	Upgrade	MMizuho	Neutral → Buy	$4 → $8	-68.7%
Oct 26, 2023	Downgrade	MMizuho	Buy → Neutral	$57 → $4	-84.3%
Oct 13, 2023	Downgrade	GGoldman	Buy → Neutral	$32 → $6	-76.5%
Sep 07, 2022	Initiated	NNeedham	Buy	$46	+80.0%
Mar 17, 2022	Initiated	GGoldman	Buy	$45	+76.1%
Jun 30, 2021	Initiated	MMizuho	Buy	$58	+127.0%
May 27, 2021	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$52	+103.5%
Nov 09, 2020	Upgrade	GGoldman	Neutral → Buy	$34 → $36	+40.9%
Oct 08, 2020	Initiated	TTruist	Buy	$38	+48.7%
Feb 25, 2020	Initiated	GGuggenheim	Buy	$36	+40.9%
Feb 25, 2020	Initiated	GGoldman	Neutral	$30	+17.4%
Feb 25, 2020	Initiated	CCowen	Outperform	$55	+115.3%
Feb 25, 2020	Initiated	CCantor Fitzgerald	Overweight	$50	+95.7%

Today 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.37%
Nov-05-26 08:00AM	Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis (GlobeNewswire) -20.70%
Nov-04-26 07:00PM	Arcutis Misses Badly On Earnings As A Spending Surge Overshadows A ZORYVE Revenue Beat And Higher Guidance (Earnings Whispers) +6.41%
04:00PM	Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-26 09:00AM	Arcutis Appoints Rob Scott, MD to Board of Directors (GlobeNewswire)
04:00PM	Loading…
Oct-27-26 04:00PM	Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire)
03:29PM	Arcutis Must Prove Zoryve Volume Can Carry Growth As Pricing Tailwind Fades (Earnings Whispers)
Oct-21-26 04:00PM	Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026 (GlobeNewswire)
Oct-09-26 08:00AM	Arcutis Presents ZORYVE (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical (GlobeNewswire) +8.53%
Oct-06-26 08:19AM	Arcutis' ZORYVE (roflumilast) Wins 2026 Marie Claire Beauty Award (GlobeNewswire)
Oct-02-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-26 09:15AM	Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options (GlobeNewswire)
Sep-17-26 03:20AM	Heres What Arcutis CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11% (TIKR)
Sep-04-26 07:15PM	Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 (PR Newswire)
04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:00PM	Loading…
Sep-02-26 04:00PM	Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-07-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-26 01:08AM	Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ... (GuruFocus.com)
Aug-05-26 04:00PM	Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-26 09:36AM	Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Q2 2026 -- GF Value Sees 57% Upside (GuruFocus.com)
Jul-16-26 09:00AM	Arcutis Expands Board of Directors with Appointment of Chris Peetz (GlobeNewswire)
Jul-15-26 04:00PM	Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 (GlobeNewswire)
Jul-09-26 01:41PM	Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment (Investor's Business Daily)
Jul-08-26 08:00AM	FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months (GlobeNewswire)
Jul-02-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-26 09:15AM	Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE (roflumilast) Indications (GlobeNewswire)
Jun-29-26 07:06PM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 (GlobeNewswire)
Jun-05-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-26 08:00AM	New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology (GlobeNewswire)
May-26-26 04:00PM	Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
04:00PM	Loading…
May-08-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-26 04:00PM	Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -14.52%
Apr-27-26 08:00AM	Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months (GlobeNewswire)
Apr-22-26 08:00AM	Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines (GlobeNewswire)
Apr-15-26 04:00PM	Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 (GlobeNewswire)
Mar-31-26 04:00PM	Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +10.45%
Mar-28-26 11:00AM	Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-26-26 05:20PM	Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating (Investor's Business Daily) -5.18%
Mar-18-26 08:00AM	Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-10-26 09:00AM	Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology (GlobeNewswire)
Mar-06-26 10:20AM	Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating (Insider Monkey)
Mar-05-26 09:00AM	Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth (GlobeNewswire)
Mar-04-26 08:09AM	Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen (MarketBeat)
Mar-03-26 08:00AM	Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis (GlobeNewswire)
Feb-27-26 04:00PM	Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference (GlobeNewswire) -5.60% -8.19%
Feb-26-26 12:04AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +5.78%
Feb-25-26 07:25PM	Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:32PM	Arcutis Biotherapeutics Q4 Earnings Call Highlights (MarketBeat)
04:00PM	Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 09:15AM	Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments (GlobeNewswire)
07:22AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-19-26 10:00AM	Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-18-26 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-11-26 06:02PM	Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal (MarketBeat)
Feb-10-26 08:32AM	Implied Volatility Surging for Arcutis Biotherapeutics Stock Options (Zacks)
Feb-05-26 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 08:00AM	Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
Jan-27-26 08:16AM	Arcutis Biotherapeutics announces termination of promotion agreement with Kowa (TipRanks)
Jan-26-26 08:00AM	Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa (GlobeNewswire)
Jan-22-26 04:00PM	Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference (GlobeNewswire)
Jan-21-26 08:00AM	Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions (GlobeNewswire)
Jan-13-26 04:21AM	Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength? (Zacks)
Jan-12-26 08:00AM	Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones (GlobeNewswire) -5.10%
Dec-19-25 09:40AM	Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? (Zacks)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-14-25 09:35AM	This Biotech Stock Could Cure Your Portfolio's Pain (Motley Fool)
Dec-10-25 12:00PM	What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-08-25 04:00PM	Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri (GlobeNewswire)
10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks)
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
Dec-05-25 10:37AM	ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study (Zacks)
10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks)
Dec-04-25 09:47AM	Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know (Zacks)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
10:01AM	AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension (Zacks)
09:40AM	Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
10:12AM	Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? (Zacks)
10:09AM	JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis (Zacks)
Dec-01-25 11:41AM	ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know (Zacks)
Nov-28-25 09:33AM	Netflix target cut, Five Below target raised: Wall Street's top analyst calls (The Fly)
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 03:47AM	Why Shares in Arcutis Biotherapeutics Surged Again This Week (Motley Fool) +7.90%
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
09:49AM	MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC (Zacks)
09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? (Zacks)
Nov-19-25 10:06AM	VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects (Zacks)
Nov-18-25 11:42AM	VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know (Zacks)
10:33AM	Alector Stock Plummets 63% in a Month: Here's What You Need to Know (Zacks)
Nov-17-25 09:41AM	Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year? (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
08:00AM	FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Nov-15-25 08:00AM	CrowdStrike Leads Five Stocks To Watch Near Buy Points (Investor's Business Daily)
Nov-14-25 07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +9.36%
Nov-13-25 09:08AM	Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint (Zacks)
08:00AM	Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis (GlobeNewswire)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Matsuda Masaru	EVP, Chief Legal Officer	Nov 04 '26	Option Exercise	3.64	40,000	145,600	151,289	Nov 04 06:38 PM
Matsuda Masaru	EVP, Chief Legal Officer	Nov 04 '26	Sale	34.32	40,000	1,372,672	111,289	Nov 04 06:38 PM
Matsuda Masaru	EVP, Chief Legal Officer	Nov 02 '26	Sale	31.86	1,219	38,841	111,289	Nov 04 06:38 PM
Burnett Patrick	EVP, Chief Medical Officer	Nov 02 '26	Sale	31.86	943	30,047	116,649	Nov 04 06:38 PM
Watanabe Todd	See Remarks	Nov 02 '26	Sale	31.86	4,377	139,466	712,826	Nov 04 06:38 PM
Masaru Matsuda	Officer	Nov 04 '26	Proposed Sale	34.32	40,000	1,372,670		Nov 04 05:16 PM
Todd Franklin Watanabe	Officer	Nov 02 '26	Proposed Sale	31.86	4,377	139,466		Nov 02 05:29 PM
Masaru Matsuda	Officer	Nov 02 '26	Proposed Sale	31.86	1,219	38,841		Nov 02 05:27 PM
Patrick Burnett	Officer	Nov 02 '26	Proposed Sale	31.86	943	30,047		Nov 02 05:27 PM
Larry Todd Edwards	Former Officer	Oct 20 '26	Proposed Sale	33.00	60,376	1,992,408		Oct 20 04:53 PM
Welgus Howard G.	Director	Oct 15 '26	Option Exercise	7.93	4,094	32,459	39,935	Oct 19 04:49 PM
Welgus Howard G.	Director	Oct 15 '26	Sale	26.93	4,728	127,325	35,207	Oct 19 04:49 PM
Howard Welgus	Director	Oct 15 '26	Proposed Sale	26.93	4,728	127,325		Oct 15 03:56 PM
Matsuda Masaru	See Remarks	Sep 16 '26	Sale	25.00	3,674	91,853	112,508	Sep 18 04:17 PM
Welgus Howard G.	Director	Sep 15 '26	Option Exercise	7.93	4,096	32,475	40,571	Sep 17 04:06 PM
Welgus Howard G.	Director	Sep 15 '26	Sale	24.18	4,730	114,371	35,841	Sep 17 04:06 PM
Larry Todd Edwards	Former Officer	Sep 16 '26	Proposed Sale	25.00	341,980	8,549,500		Sep 16 04:08 PM
Howard Welgus	Director	Sep 15 '26	Proposed Sale	24.18	4,730	114,371		Sep 15 04:03 PM
Matsuda Masaru	See Remarks	Sep 08 '26	Sale	25.03	9,989	249,986	116,182	Sep 10 07:24 PM
Masaru Matsuda	Officer	Sep 08 '26	Proposed Sale	25.03	13,663	341,933		Sep 08 04:41 PM
Curran Terrie	Director	Aug 27 '26	Option Exercise	8.30	38,200	317,180	50,578	Aug 28 05:40 PM
Curran Terrie	Director	Aug 27 '26	Sale	25.03	38,200	956,123	23,526	Aug 28 05:40 PM
Terrie Curran	Director	Aug 27 '26	Proposed Sale	25.03	38,200	956,125		Aug 27 04:05 PM
Curran Terrie	Director	Aug 20 '26	Option Exercise	7.51	1,072	8,051	24,598	Aug 24 04:19 PM
Curran Terrie	Director	Aug 20 '26	Sale	26.04	1,072	27,912	23,526	Aug 24 04:19 PM
Burnett Patrick	See Remarks	Aug 19 '26	Sale	27.00	1,697	45,819	117,592	Aug 21 04:08 PM
Terrie Curran	Director	Aug 20 '26	Proposed Sale	26.04	1,072	27,912		Aug 20 04:50 PM
Welgus Howard G.	Director	Aug 17 '26	Option Exercise	7.93	4,096	32,475	41,205	Aug 19 04:57 PM
Welgus Howard G.	Director	Aug 17 '26	Sale	26.18	4,730	123,835	36,475	Aug 19 04:57 PM
Patrick Burnett	Officer	Aug 19 '26	Proposed Sale	27.00	1,697	45,819		Aug 19 04:27 PM
Howard Welgus	Director	Aug 17 '26	Proposed Sale	26.18	4,730	123,835		Aug 17 04:28 PM
Burnett Patrick	See Remarks	Aug 11 '26	Option Exercise	3.64	8,300	30,212	127,589	Aug 13 08:06 PM
Burnett Patrick	See Remarks	Aug 12 '26	Option Exercise	3.64	6,700	24,388	125,989	Aug 13 08:06 PM
Burnett Patrick	See Remarks	Aug 11 '26	Sale	26.52	8,300	220,129	119,289	Aug 13 08:06 PM
Burnett Patrick	See Remarks	Aug 12 '26	Sale	26.08	6,700	174,767	119,289	Aug 13 08:06 PM
Patrick Burnett	Officer	Aug 11 '26	Proposed Sale	26.52	15,000	397,824		Aug 11 05:16 PM
Burnett Patrick	See Remarks	Aug 03 '26	Sale	26.12	955	24,942	119,289	Aug 05 09:42 PM
Matsuda Masaru	See Remarks	Aug 03 '26	Sale	26.12	1,230	32,124	126,171	Aug 05 09:42 PM
Watanabe Todd	See Remarks	Aug 03 '26	Sale	26.12	4,375	114,261	717,203	Aug 05 09:42 PM
Matsuda Masaru	Officer	Aug 03 '26	Proposed Sale	26.12	1,230	32,124		Aug 03 05:07 PM
Todd Frank Watanabe	Officer	Aug 03 '26	Proposed Sale	26.12	4,375	114,261		Aug 03 05:07 PM
Patrick Burnett	Officer	Aug 03 '26	Proposed Sale	26.12	955	24,942		Aug 03 05:07 PM
Welgus Howard G.	Director	Jul 15 '26	Option Exercise	7.93	4,096	32,475	41,839	Jul 17 04:01 PM
Welgus Howard G.	Director	Jul 15 '26	Sale	26.91	4,730	127,284	37,109	Jul 17 04:01 PM
Howard Welgus	Director	Jul 15 '26	Proposed Sale	26.91	4,730	127,284		Jul 15 04:01 PM
LIN SUE-JEAN	Director	Jun 15 '26	Sale	24.38	4,946	120,587	27,567	Jun 17 08:47 PM
Welgus Howard G.	Director	Jun 15 '26	Option Exercise	7.93	4,096	32,475	42,474	Jun 17 08:40 PM
Welgus Howard G.	Director	Jun 15 '26	Sale	24.41	4,096	99,980	38,378	Jun 17 08:40 PM
Welgus Howard G.	Director	Jun 17 '26	Sale	25.67	635	16,300	37,743	Jun 17 08:40 PM
Howard Welgus	Director	Jun 17 '26	Proposed Sale	25.67	635	16,300		Jun 17 04:08 PM
Sue-Jean Lin	Officer	Jun 15 '26	Proposed Sale	24.38	4,946	120,587		Jun 15 04:11 PM
Howard Welgus	Director	Jun 15 '26	Proposed Sale	24.41	4,096	99,980		Jun 15 04:11 PM
Vairavan Latha	SVP Chief Financial Officer	May 11 '26	Sale	21.05	435	9,157	85,978	May 13 07:43 PM
Burnett Patrick	See Remarks	May 11 '26	Sale	21.05	222	4,673	120,244	May 13 07:42 PM
Patrick Burnett	Officer	May 11 '26	Proposed Sale	21.05	222	4,673		May 11 04:44 PM
Latha Vairavan	officer	May 11 '26	Proposed Sale	21.05	435	9,157		May 11 04:35 PM
Matsuda Masaru	See Remarks	May 04 '26	Sale	23.31	8,256	192,415	126,689	May 06 07:40 PM
Burnett Patrick	See Remarks	May 04 '26	Sale	23.61	684	16,150	120,466	May 06 06:15 PM
Vairavan Latha	SVP Chief Financial Officer	May 04 '26	Sale	23.61	1,341	31,662	86,413	May 06 06:13 PM
Watanabe Todd	See Remarks	May 04 '26	Sale	23.61	3,172	74,893	720,755	May 06 06:06 PM
Welgus Howard G.	Director	May 01 '26	Sale	22.99	7,144	164,220	32,600	May 05 08:21 PM
Patrick Burnett	Officer	May 04 '26	Proposed Sale	23.61	684	16,150		May 04 05:19 PM
Latha Vairavan	Officer	May 04 '26	Proposed Sale	23.61	1,341	31,662		May 04 05:18 PM
Todd Watanabe	Officer	May 04 '26	Proposed Sale	23.61	3,172	74,893		May 04 05:18 PM
Masaru Matsuda	officer	May 04 '26	Proposed Sale	23.31	8,256	192,416		May 04 05:05 PM
Howard Welgus	Director	May 01 '26	Proposed Sale	22.99	7,144	164,220		May 01 04:04 PM
Welgus Howard G.	Director	Apr 01 '26	Sale	23.88	10,000	238,801	39,744	Apr 03 05:46 PM
Howard Welgus	Director	Apr 01 '26	Proposed Sale	23.88	10,000	238,801		Apr 01 04:02 PM
Leonard Keith R	Director	Mar 02 '26	Option Exercise	8.28	39,272	325,231	61,395	Mar 04 04:17 PM
Leonard Keith R	Director	Mar 02 '26	Sale	25.39	39,272	997,195	22,123	Mar 04 04:17 PM
Welgus Howard G.	Director	Mar 02 '26	Sale	25.65	10,000	256,518	49,744	Mar 04 04:16 PM
Edwards Larry Todd	See Remarks	Mar 02 '26	Sale	25.18	3,687	92,846	175,178	Mar 03 08:43 PM
Watanabe Todd	See Remarks	Mar 02 '26	Sale	25.18	37,349	940,528	785,957	Mar 03 08:42 PM
Matsuda Masaru	See Remarks	Mar 02 '26	Sale	25.30	8,733	220,943	136,932	Mar 03 08:42 PM
Matsuda Masaru	See Remarks	Feb 27 '26	Sale	27.95	3,325	92,934	143,678	Mar 03 08:42 PM
Vairavan Latha	SVP Chief Financial Officer	Mar 02 '26	Sale	25.18	2,853	71,844	87,754	Mar 03 08:42 PM
Burnett Patrick	See Remarks	Mar 02 '26	Sale	25.18	6,287	158,320	121,150	Mar 03 08:41 PM
Masaru Matsuda	officer	Mar 02 '26	Proposed Sale	26.03	12,058	313,878		Mar 02 06:48 PM
Larry Todd Edwards	Officer	Mar 02 '26	Proposed Sale	25.18	3,687	92,846		Mar 02 06:22 PM
Todd Watanabe	Officer	Mar 02 '26	Proposed Sale	25.18	37,349	940,526		Mar 02 06:22 PM
Latha Vairavan	officer	Mar 02 '26	Proposed Sale	25.18	2,853	71,845		Mar 02 06:22 PM
Patrick Burnett	Officer	Mar 02 '26	Proposed Sale	25.18	6,287	158,320		Mar 02 06:21 PM
Keith Leonard	Board of Director	Mar 02 '26	Proposed Sale	25.39	39,272	997,195		Mar 02 05:59 PM
Howard Welgus	Director	Mar 02 '26	Proposed Sale	25.65	10,000	256,518		Mar 02 05:25 PM
Matsuda Masaru	See Remarks	Feb 02 '26	Sale	25.28	40,638	1,027,293	110,003	Feb 04 08:35 PM
Burnett Patrick	See Remarks	Feb 04 '26	Sale	25.81	9,794	252,748	80,651	Feb 04 07:30 PM
Burnett Patrick	See Remarks	Feb 02 '26	Sale	25.50	3,675	93,707	90,445	Feb 04 07:30 PM
Watanabe Todd	See Remarks	Feb 02 '26	Sale	25.50	19,833	505,710	721,306	Feb 04 07:25 PM
Vairavan Latha	SVP Chief Financial Officer	Feb 02 '26	Sale	25.50	1,320	33,658	63,607	Feb 04 07:24 PM
Welgus Howard G.	Director	Feb 02 '26	Sale	25.05	10,000	250,483	59,744	Feb 04 07:23 PM
Edwards Larry Todd	See Remarks	Feb 02 '26	Sale	25.50	2,052	52,323	148,865	Feb 04 07:21 PM
Patrick Burnett	Officer	Feb 04 '26	Proposed Sale	25.81	9,794	252,748		Feb 04 04:52 PM
Masaru Matsuda	officer	Feb 02 '26	Proposed Sale	25.28	40,638	1,027,275		Feb 02 06:19 PM
Todd Edwards	Officer	Feb 02 '26	Proposed Sale	25.50	2,052	52,323		Feb 02 06:17 PM
Latha Vairavan	Officer	Feb 02 '26	Proposed Sale	25.50	1,320	33,658		Feb 02 06:15 PM
Patrick Burnett	Officer	Feb 02 '26	Proposed Sale	25.50	3,675	93,707		Feb 02 05:48 PM
Todd Frank Watanabe	officer	Feb 02 '26	Proposed Sale	25.50	19,833	505,710		Feb 02 05:41 PM
Howard Welgus	Director	Feb 02 '26	Proposed Sale	25.05	10,000	250,483		Feb 02 05:04 PM
Burnett Patrick	See Remarks	Jan 05 '26	Sale	28.98	2,490	72,166	94,120	Jan 07 05:46 PM
Welgus Howard G.	Director	Jan 02 '26	Sale	28.96	10,000	289,606	69,744	Jan 06 05:31 PM

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

PresidentMr. Todd Franklin Watanabe M.A.

Co-Founder & Director EmeritusDr. Bhaskar Chaudhuri Ph.D.

Senior VP & Chief Financial OfficerMs. Latha Vairavan

J.D.Mr. Masaru Matsuda Esq.

Ph.D.Dr. Patrick E. Burnett M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARQT

Arcutis Biotherapeutics Inc

Upgrade your Finviz experience